Chronic idiopathic urticaria

Summary

Chronic idiopathic urticaria (MONDO:0044212) is a disease and 23 clinical trials. Top therapeutic interventions include desloratadine, omalizumab, and diphenhydramine. A subtype of idiopathic urticaria — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 23

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chronic idiopathic urticaria
Mondo ID	MONDO:0044212
DOID	DOID:0080749
SNOMED CT	302162004
UMLS	C0578870
MedGen	662267
Is cancer (heuristic)	no

Also known as: idiopathic urticaria, chronic

Disease family

This is a subtype of idiopathic urticaria. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › urticaria › idiopathic urticaria › chronic idiopathic urticaria

Related subtypes (1): acute idiopathic urticaria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 23.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	7
PHASE2	6
PHASE4	5
PHASE2/PHASE3	2
Not specified	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00264303	PHASE4	COMPLETED	CUTE (Chronic Urticaria Treatment Evaluation)
NCT00346606	PHASE4	UNKNOWN	The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria
NCT00536380	PHASE4	COMPLETED	Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)
NCT00783354	PHASE4	COMPLETED	A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)
NCT03183024	PHASE4	COMPLETED	Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody
NCT07486583	PHASE3	NOT_YET_RECRUITING	Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.
NCT00757562	PHASE3	COMPLETED	Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)
NCT01030120	PHASE2/PHASE3	WITHDRAWN	Etanercept for the Treatment of Chronic Urticaria
NCT01264939	PHASE3	COMPLETED	A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
NCT01287117	PHASE3	COMPLETED	A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
NCT01292473	PHASE3	COMPLETED	A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
NCT01803763	PHASE2/PHASE3	COMPLETED	Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
NCT02166151	PHASE3	UNKNOWN	Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
NCT05774639	PHASE3	COMPLETED	Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
NCT00866788	PHASE2	COMPLETED	A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
NCT01599637	PHASE2	COMPLETED	Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
NCT01635127	PHASE2	UNKNOWN	Efficacy Study of Canakinumab to Treat Urticaria
NCT02031679	PHASE2	COMPLETED	Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines
NCT03858634	PHASE2	COMPLETED	A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
NCT05936567	PHASE2	COMPLETED	Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
NCT04175704	PHASE1	UNKNOWN	Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria
NCT02814630	Not specified	COMPLETED	Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria
NCT03406325	Not specified	COMPLETED	Mast Cell Activation Test in Allergic Disease

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DESLORATADINE	4	5
OMALIZUMAB	4	5
DIPHENHYDRAMINE	4	2
BENRALIZUMAB	4	1
CANAKINUMAB	4	1
ETANERCEPT	4	1
LEVOCETIRIZINE	4	1
POVORCITINIB	3	1
AZD1981	2	1
VIXARELIMAB	2	1